A Pragmatic Step, but One That Warrants Caution –

President Donald Trump signed an government order Thursday directing federal companies to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act. This shift acknowledges the drug’s potential medical makes use of while inserting it alongside substances like ketamine and codeine-laced Tylenol, which carry average dangers of dependence.

READ MORE: Executive High: Trump Reclassifies Marijuana for Health Gains

The transfer builds on a course of initiated under the Biden administration but stalled by inaction for years. Trump emphasised that the order facilitates important research into marijuana’s advantages and risks without legalizing leisure use nationwide. “This reclassification order will make it far easier to conduct marijuana-related medical research,” he said during the Oval Office signing, noting its “tremendously positive impact” on learning therapies for chronic circumstances.

NOW – Trump indicators government order reclassifying marijuana from a schedule 1 to a schedule 3 drug, stress-free rules. pic.twitter.com/nZdECCYzkN

— Disclose.television (@disclosetv) December 18, 2025

From my view, this resolution displays sensible governance over inflexible ideology. For many years, the Schedule I designation — grouping marijuana with heroin and LSD — has hindered reliable scientific inquiry, despite growing evidence of therapeutic functions for pain management, epilepsy, and other illnesses. Easing these limitations aligns with federalism ideas, permitting states to continue experimenting while the federal authorities catches up to actuality. It also relieves undue tax burdens on medical hashish suppliers, fostering financial effectivity without increasing authorities overreach. 

President Trump has signed an order reclassifying marijuana from Schedule I (heroin, LSD) to Schedule III (Tylenol, Ketamine)
It has medical functions. This was the appropriate factor to do.

pic.twitter.com/e06eb92I5l

— The Redheaded libertarian (@TRHLofficial) December 18, 2025

It’s jogged my memory of conservative commentator Michelle Malkin and her daughter. In 2017, the lifelong “drug warrior” famously talked about her daughter’s use of CBD oil in an op-ed titled “Keep Your Hands Off My Daughter’s Marijuana.” Malkin’s daughter, Veronica, suffered from a debilitating thriller sickness that left her bedridden and gasping for air — a condition that failed to reply to a “alphabet soup” of conventional, FDA-approved prescribed drugs. 

I help AG Sessions on many core points, but disagree with him emphatically on marijuana coverage. And I’m not a doctor either.
Just an informed conservative mother==>https://t.co/4n608bHKTohttps://t.co/elPxd9U3nE https://t.co/FXnDI530oO

— Michelle Malkin (@michellemalkin) December 7, 2017

When neurologists advised CBD oil, Malkin discovered herself caught between federal law and her youngster’s survival. She argued that the federal authorities’s refusal to acknowledge marijuana’s medical utility was not just a scientific error, but an affront to parental rights and particular person liberty.

By shifting marijuana to Schedule III, the administration successfully solutions Malkin’s plea to “let the scientists lead,” transferring the drug out of the same class as heroin and into the same class as prescription drugs like Tylenol with codeine. For “liberty-loving moms” like Malkin, this coverage shift represents the federal authorities finally stepping out of the doctor-patient relationship and acknowledging that, for many households, this is a matter of medical necessity slightly than a cultural debate.

Yet the backlash from within Republican ranks deserves consideration. Lawmakers like Rep. Pete Sessions (TX-17) and Rep. Andy Harris (MD-01), along with a broader coalition, warned in a letter to the president that reclassification might ship combined alerts to younger people, fuel habit trends, and not directly benefit cartels profiting from black-market demand. These considerations aren’t baseless. 

Marijuana use among adolescents correlates with greater dangers of mental health points and gateway patterns to more durable medication, as research from the National Institute on Drug Abuse persistently show. Road security data from states with liberalized legal guidelines reveal elevated impaired-driving incidents, straining public sources. Trump’s administration has in any other case pursued a powerful stance on illicit medication, designating major cartels as terrorist organizations and authorizing strikes against trafficking vessels. 

This context underscores that reclassification targets medical oversight, not normalization of leisure habits. Still, conservatives ought to stay vigilant. Loosening federal restrictions dangers normalizing a substance whose long-term societal prices — misplaced productiveness, household pressure, emergency room visits — often fall on taxpayers.

Ultimately, Trump’s order strikes a steadiness: advancing science and affected person aid without endorsing broader liberalization. It respects states’ rights and evidence-based coverage, but only if paired with sturdy enforcement against abuse and trafficking. Lawmakers on both sides would do properly to monitor outcomes intently, making certain this pragmatic adjustment doesn’t erode the cultural and legal guardrails that shield weak communities.

Editor’s Note: Do you get pleasure from RedState’s conservative reporting that takes on the novel left and woke media? Support our work so that we will continue to carry you the reality.

Join RedState VIP and use the promo code MERRY74 to obtain 74% off your membership.